ReviewCureus2022
Co-prescription of Dual-Antiplatelet Therapy and Proton Pump Inhibitors: Current Guidelines.
Review in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A network meta-analysis: evaluating the efficacy and safety of concurrent proton pump inhibitors and clopidogrel therapy in post-PCI patients.Frontiers in cardiovascular medicine · 2024Pooled it
- Comparing Major Gastrointestinal Bleeding in Patients Receiving Edoxaban Versus Warfarin After Transcatheter Aortic Valve Replacement: Results From the Randomized ENVISAGE-TAVI AF Trial.Journal of the American Heart Association · 2025Trial
- Drug Utilization Pattern of Proton Pump Inhibitors in Patients with Acid Peptic Disease and Comorbidities in India: A Real-World Electronic Medical Records-Based Study.Drugs - real world outcomes · 2026Article
- Polypharmacy and Drug-Drug Interaction Architecture in Hospitalized Cardiovascular Patients: Insights from Real-World Analysis.Biomedicines · 2026Article
- Observational
- Association of P2RY12 Gene Variants and Non-Genetic Factors With Clopidogrel Responsiveness in Vietnamese Patients After Percutaneous Coronary Intervention: A Cross-Sectional Study.Journal of clinical laboratory analysis · 2025Article
- Risk Factors for Upper Gastrointestinal Bleeding in Patients Undergoing Percutaneous Coronary Intervention on Dual Antiplatelet Therapy with Assessment of Anti-Ulcer Medication Effects.Acta Cardiologica Sinica · 2025Article
- PPI in preventing gastrointestinal injury in minor ischemic stroke or TIA patients at low risk of gastrointestinal bleeding treated with short-term dual antiplatelet therapy.Frontiers in pharmacology · 2025Article
- Article
- Pattern of Prescribing Proton Pump Inhibitors: Evaluating Appropriateness and Factors Contributing to Their Adverse Effect Reaction Risk.Journal of clinical medicine · 2024Article
- From genes to drugs:Frontiers in pharmacology · 2024Review
- Cardiovascular Compatibility of Proton Pump Inhibitors: Practice Recommendations.Cardiology and therapy · 2023Article
- Impact of Concomitant Use of Proton Pump Inhibitors and Clopidogrel on Recurrent Stroke and Myocardial Infarction.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Proton pump inhibitors display anti-tumour potential in glioma.Cell proliferation · 2023Review
- Current management of gastro-oesophageal reflux disease-treatment costs, safety profile, and effectiveness: a narrative review.Gastroenterology report · 2023Review
- Antiplatelet Therapy Aims and Strategies in Asian Patients with Acute Coronary Syndrome or Stable Coronary Artery Disease.Journal of clinical medicine · 2022Review
- Comparison of the Degree of Gastric Mucosal Injury between Patients Who Are Receiving Dual Antiplatelet Therapy or Single Antiplatelet Therapy.Diagnostics (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dual-antiplatelet therapy (DAPT) prevents thrombotic complications associated with coronary artery disease, acute coronary syndrome, and stent thrombosis following the percutaneous coronary intervention or coronary artery bypass grafting. When initiating DAPT, the risk of thrombosis must be balanced with the increased risk of upper gastrointestinal bleed (UGIB). Proton-pump inhibitors (PPIs) are concurrently prescribed with DAPT to reduce bleeding risk. In this review, we discuss the benefits and potential complications of DAPT/PPI co-prescription. The only large international randomized control trial (RCT), Clopidogrel and the Optimization of Gastrointestinal Events Trial (COGENT), shows robust evidence that PPIs are a safe and effective method to reduce the risk of bleeding in patients on DAPT. However, more large-scale RCTs are needed to study potential long-term effects and draw a stronger conclusion on this topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.